- GlobeNewswire•12 days agoAddex ADX71441 Demonstrates Statistically Significant Efficacy in a Highly Translational Preclinical Model of Chronic Osteoarthritis Pain
Geneva, Switzerland, 9 January 2017 - Addex Therapeutics (SIX: ADXN), announced today that ADX71441, a positive allosteric modulator (PAM) of the gamma-aminobutyric acid subtype B (GABAB) receptor demonstrated ...
- GlobeNewswire•last month
Geneva, Switzerland, 13 December 2016 - Addex Therapeutics (SIX: ADXN), announced today that the pharmacological profile of ADX71441, gamma-aminobutyric acid subtype B (GABAB) receptor positive allosteric ...
- Accesswire•6 months ago
Developing allosteric modulators to treat a wide range of CNS disorders; Report Available here: www.lifescicapital.com/equity-research/addex/ NEW YORK, NY / ACCESSWIRE / July 19, 2016 / LifeSci Capital, ...
ADXN.SW : Summary for ADDEX N - Yahoo Finance
ADDEX N (ADXN.SW)
Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
|Day's Range||2.25 - 2.30|
|52 Week Range||1.70 - 3.11|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|